In an elderly patient (≥65 years), is dexamethasone appropriate as an appetite stimulant?

Dexamethasone for Appetite Stimulation in Elderly Patients

Dexamethasone should NOT be used as an appetite stimulant in elderly patients, particularly those with dementia, and has limited evidence supporting its use even in non-dementia elderly populations.

Critical Distinction: Dementia vs. Non-Dementia Elderly

Elderly Patients WITH Dementia

Pharmacological appetite stimulants, including dexamethasone, are explicitly contraindicated in persons with dementia. 1

• The 2024 ESPEN guidelines (89% consensus) state that drugs to stimulate appetite or weight gain should NOT be used in persons with dementia 1
• Evidence from multiple trials shows inconsistent benefits and potentially harmful side effects that outweigh uncertain gains in this population 1
• All appetite stimulation efforts in dementia patients must focus exclusively on non-pharmacologic interventions 2

Elderly Patients WITHOUT Dementia

Dexamethasone has very limited evidence for appetite stimulation in elderly patients and carries significant risks that likely outweigh modest, short-term benefits.

Evidence Quality and Efficacy

• A 2016 prospective study (114 patients, mean age 71) showed that 68.5% of patients had ≥1 reduction in anorexia scores at day 7 with dexamethasone (mean dose 4.1 mg/day) 3
• However, a 2021 phase III randomized controlled trial found no difference between dexamethasone 4 mg/day and placebo for appetite improvement at week 1 (65.5% vs 58.5% responders, p=0.067) 4
• A 2008 study in lung cancer patients showed dexamethasone significantly decreased appetite loss but had no influence on appetite improvement or weight gain 5

Significant Safety Concerns

Adverse events are frequent and clinically meaningful:

• 32.4% of patients experienced ≥1 harms including insomnia (n=10), depression (n=7), euphoria (n=7), and hyperglycemia (n=7) in the 2016 study 3
• The 2021 RCT reported treatment-emergent adverse events in 90.4% of participants, with hyperglycemia and deep vein thromboses more frequent with dexamethasone than placebo 4
• Dexamethasone causes substantial glycemic variability, with patients experiencing mean plasma glucose increases of 0.7-2.4 mmol/L depending on baseline glycemic status 6
• Dexamethasone may mask signs of impending death (being bedbound, only drinking sips, subcomatose state), making recognition of the dying phase difficult and causing severe impact on relatives and care teams 7

Mechanism Paradox

• Dexamethasone induces a rapid and sustained rise in circulating leptin levels (a proposed satiety factor), increasing by 123% within 24 hours 8
• Despite increasing leptin (a satiety signal), dexamethasone stimulates appetite, suggesting the mechanism is poorly understood and regulation of appetite is multifactorial 8

Recommended Approach for Elderly Patients

Step 1: Screen for Dementia

• If dementia is present, STOP here—do not use any pharmacological appetite stimulants 1, 2

Step 2: Identify and Address Reversible Causes

• Medication review to minimize adverse drug effects on food intake (opioids, sedatives, digoxin, metformin, antibiotics, NSAIDs) 1
• Dental evaluation and treatment for poor dentition 2
• Speech therapy evaluation for dysphagia 2
• Adequate pain management 1
• Treatment of depression (if present, consider mirtazapine which may improve appetite as a side effect) 1, 2

Step 3: Implement Non-Pharmacologic Interventions (2-4 weeks trial)

• High-density nutritional supplements and fortified foods 2
• Dietary counseling with registered dietitian 2
• Environmental modifications: supervision during meals, verbal prompting, feeding assistance 1, 2
• Social interventions: encourage shared meals, meals-on-wheels programs 1, 2

Step 4: Consider Alternative Pharmacologic Options (NOT Dexamethasone)

If non-pharmacologic measures fail after 2-4 weeks:

• First-line: Mirtazapine 30 mg daily (especially if concurrent depression exists) 2

  • Evidence shows mean weight gain of 1.9 kg at 3 months 2
  • Monitor for excessive daytime sedation 2

• Alternative: Megestrol acetate (with significant caveats) 2

  • Mixed evidence for efficacy 1, 2
  • Contraindicated in patients undergoing physical rehabilitation as it may impede functional gains 2
  • Associated with thromboembolic events and edema 9

Step 5: Monitoring and Discontinuation

• Weekly weights initially 2
• Discontinue if no benefit after 6-12 weeks or if adverse effects emerge 2

Why Dexamethasone Is Not Appropriate

The 2020 ASCO guideline on cancer cachexia management notes that corticosteroids (including dexamethasone) improve appetite but do not consistently improve weight, and optimal dose and duration remain unknown. 9

• Benefits are short-term (typically <7 days) with no sustained weight gain 3, 5
• High rate of adverse events (>30%) including metabolic, psychiatric, and thrombotic complications 3, 4
• No superiority over placebo in the highest quality randomized trial 4
• May mask dying phase, causing distress to families and care teams 7
• FDA labeling indicates dexamethasone dosing of 0.5-9 mg/day for various conditions, but appetite stimulation is not an approved indication 10

Common Pitfalls to Avoid

• Never use dexamethasone or any appetite stimulant as first-line therapy without addressing underlying causes and attempting non-pharmacologic interventions 2
• Never prescribe appetite stimulants to elderly patients with dementia regardless of weight loss severity 1, 2
• Do not use dexamethasone in elderly patients undergoing physical therapy or rehabilitation as corticosteroids may impair functional recovery 2
• Avoid long-term use (>48-72 hours for high-dose therapy per FDA labeling; >7 days for appetite stimulation per research evidence) 10, 3
• Do not ignore hyperglycemia risk, especially in patients with prediabetes or diabetes, where dexamethasone causes frequent diabetic events 6